drugset / Trial / NCT00225550

A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

NCT00225550

Phase 1/2 Terminated Adherex Technologies, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ADH-1 Protein / enzyme biologic Intravenous

Indications